Connect your AI

Sutro Biopharma STRO Total Liabilities

Total Liabilities at other companies

PfizerPFE

$3.41B-97.1%

RegenxbioRGNX

$320.81M+48.0%

Nuvectis Pharma, Inc.NVCT

$11.18M+21.6%

XencorXNCR

$221.21M-16.5%

SchrodingerSDGR

$320.64M-13.2%

Roivant SciencesROIV

$416.28M+66.7%

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's total liabilities?: Sutro Biopharma (STRO) reported total liabilities of $308.88M in Q1 2026.
How has Sutro Biopharma's total liabilities changed year-over-year?: Sutro Biopharma's total liabilities decreased by 11.0% year-over-year, from $347.24M to $308.88M.
What is the long-term trend for Sutro Biopharma's total liabilities?: Over 5 years (2020 to 2025), Sutro Biopharma's total liabilities has grown at a 37.6% compound annual growth rate (CAGR), from $62.06M to $306.28M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.